Vanguard Group Inc. raised its holdings in shares of Cryolife Inc (NYSE:CRY) by 3.5% in the 2nd quarter, Holdings Channel reports. The firm owned 2,277,862 shares of the medical equipment provider’s stock after purchasing an additional 76,680 shares during the quarter. Vanguard Group Inc. owned about 0.06% of Cryolife worth $68,176,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also added to or reduced their stakes in the business. Laurion Capital Management LP bought a new stake in Cryolife during the second quarter valued at $276,000. Pinebridge Investments L.P. boosted its holdings in shares of Cryolife by 196.2% during the second quarter. Pinebridge Investments L.P. now owns 38,366 shares of the medical equipment provider’s stock valued at $1,148,000 after acquiring an additional 25,413 shares during the period. United Capital Financial Advisers LLC acquired a new position in shares of Cryolife during the second quarter valued at $786,000. Northern Trust Corp boosted its holdings in shares of Cryolife by 0.6% during the second quarter. Northern Trust Corp now owns 1,179,970 shares of the medical equipment provider’s stock valued at $35,316,000 after acquiring an additional 7,499 shares during the period. Finally, THB Asset Management boosted its holdings in shares of Cryolife by 1.6% during the second quarter. THB Asset Management now owns 272,590 shares of the medical equipment provider’s stock valued at $8,158,000 after acquiring an additional 4,375 shares during the period. Hedge funds and other institutional investors own 70.71% of the company’s stock.
CRY stock opened at $23.25 on Friday. The company has a quick ratio of 3.82, a current ratio of 5.03 and a debt-to-equity ratio of 0.83. The company has a 50-day simple moving average of $26.86 and a 200 day simple moving average of $28.67. Cryolife Inc has a fifty-two week low of $22.30 and a fifty-two week high of $33.78. The company has a market capitalization of $859.40 million, a P/E ratio of 89.42 and a beta of 0.64.
Several equities analysts have recently issued reports on the stock. ValuEngine downgraded shares of Cryolife from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 1st. Canaccord Genuity set a $35.00 price target on shares of Cryolife and gave the company a “buy” rating in a report on Wednesday, July 31st. Finally, Zacks Investment Research raised shares of Cryolife from a “hold” rating to a “buy” rating and set a $26.00 price target for the company in a report on Friday. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $30.66.
Cryolife Company Profile
CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.
See Also: Overbought
Want to see what other hedge funds are holding CRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cryolife Inc (NYSE:CRY).
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.